Work

Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.e23064

Authors: Hai T. Tran, Yasir Elamin, George R. Simon, George R. Blumenschein, Anne S. Tsao, Vassiliki Papadimitrakopoulou, Don Lynn Gibbons, Frank V. Fossella, Richard Burnham Lanman, Kimberly C. Banks, Lauren Averett Byers, Jianjun Zhang, John Heymach

Institutions: The University of Texas MD Anderson Cancer Center, Guardant (United States)

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890247770

Cites:

Cited by:

Related to: 10